Browse Articles
Discover research articles across all indexed journals
Bidirectional relationship between epigenetic age and stroke, dementia, and late-life depression
Dynamic Redox Induced Localized Charge Accumulation Accelerating Proton Exchange Membrane Electrolysis
AbstractThe sluggish anodic oxygen evolution reaction (OER) in proton exchange membrane (PEM) electrolysis necessitates applied bias to facilitate electron transfer as well as bond cleavage and formation. Traditional electrocatalysis focuses on analyzing the effects of electron transfer, while the role of charge accumulation induced by the applied overpotential has not been thoroughly investigated. To explore the influence mechanism of bias‐driven charge accumulation, capacitive Mn is incorporated into IrO2 to regulate the local electronic structure and the adsorption behavior. The applied bias triggers dynamic redox reactions at the active sites, which introduce local charge accumulation on the surface of electrocatalyst. Under bias, Mn oxidation induced a noticeable pseudocapacitance in the pre‐OER region, promoting the OER kinetics of iridium sites. Meanwhile, the increased oxygen vacancy formation energy further prevents the lattice oxygen activation. The PEM electrolyzer, equipped with optimal materials as an anode, operates at a low driving voltage of 1.637 V under 2.0 A cm−2, maintaining stable performance for over 800 h with a low degradation rate (19.4 µV h−1). This work provides insights into the performance of metal oxide catalysts in acidic environments and offers forward‐looking strategies for enhancing the catalytic performance through dynamic redox induced capacitive behavior.
Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer.
288 Background: TILs are a promising biomarker in various cancers, including colorectal cancer (CRC). Advances in deep learning enable objective and efficient TIL assessment. This study applies a novel deep learning model to quantify TIL density in a large cohort of CRC tumors, examining its relationship with clinicopathologic factors and survival. Methods: We applied a deep learning model (Deep-ICP) to H&E-stained images from CRC patients treated at Dana-Farber Cancer Center to quantify TIL density (immune cells/mm²). Kruskal-Wallis and Wilcoxon tests were used to compare categories. Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. Cox proportional hazards models analyzed the association between TIL density tertiles (lower, middle, upper) and OS, adjusting for age, sex, stage, biopsy site, tumor mutational burden (TMB, mutations/megabase), and mismatch repair (MMR) status. Results: Of 1,477 tumor specimens tested, 1,039 (70%) were primary and 438 were metastatic. The most common sites of metastasis were liver (n=205), lung (n=86), and soft tissue (n=35). The median age at diagnosis was 56 (range 19–91) years and 706 were female (48%). Most tumors (1,214/1,300; 93%) were MMR proficient (MMRp); 86 were MMR deficient (MMRd). Median TIL density was 664 (interquartile range; 469–934) cells/mm² in primary tumors, 478 (358–685) cells/mm² in liver metastases, 415 (251–645) cells/mm2 in soft tissue (p<0.001). MMRd tumors had higher median TIL density than MMRp (881 vs. 620 cells/mm²; p<0.001). After adjusting for covariates, patients with highest TIL tertile had significantly longer OS than patients with lowest TIL tertile (median OS: 75.4 [95%CI 67.4-87] months; 100.5 [83.9-116] months and 99.1 [92.4-157] months for lower, middle and upper TIL tertiles respectively; Table). In the MMRp subset, higher TIL density was still predictive of improved OS (p adj=0.010). Conclusions: This study demonstrates the feasibility of deep learning powered TIL quantification in CRC, potentially informing differences in tumor microenvironment and prognostication. Future prospective studies are needed to validate the results and explore their therapeutic implications in personalized CRC management. Variable Hazard Ratio (95% CI) P-value TIL upper tertile (vs. lower) 0.70 (0.50-0.99) 0.04 TIL middle tertile (vs. lower) 1.04 (0.77-1.39) 0.80 Age (continuous) 1.02 (1.00-1.03) 0.008 Male (vs. female) 1.13 (0.86-1.47) 0.38 Stage II (vs. stage I) 4.8 (0.59-40) 0.14 Stage III (vs. stage I) 9.4 (1.20-73) 0.03 Stage IVA (vs. stage I) 23 (2.94-178) 0.003 Stage IVB (vs. stage I) 46 (5.6-369) 0.0003 Liver specimen (vs. primary) 1.39 (1.00-1.92) 0.050 Lung specimen (vs. primary) 0.78 (0.47-1.29) 0.33 Lymph node specimen (vs. primary) 0.77 (0.27-2.17) 0.62 Other metastasis (vs. primary) 1.23 (0.78-1.93) 0.37 TMB≥10 (vs. <10) 1.17 (0.82-1.68) 0.38 MMRd (vs. MMRp) 0.65 (0.29-1.46) 0.30
Use of gene expression profiling to examine association between MUC1 and claudin 18 in gastrointestinal cancers: Implications for targeted therapies.
838 Background: Gastrointestinal tract cancers exhibit considerable molecular heterogeneity, which requires a detailed understanding of their distinct genetic profiles. Understanding the gene expression of other genes along with Claudin 18 (CLDN18) could provide insights into their interactions. Methods: We conducted a retrospective analysis of NGS profiling on 1,043 GI cancer tissue samples from three cohorts: Upper and Lower Gastrointestinal Cancer Cohort (GICC; n=651), Pancreaticobiliary Cancer Cohort (PBCC; n=316), and Hepatocellular Carcinoma Cohort (HCC; n=76). Immunohistochemistry data for PD-L1, Her2 and MMR proteins, NGS based Tumor mutation burden (TMB) and gene expression profiling (GEP) of 20,802 genes including CLDN18 was examined in a subset by targeted transcriptome profiling. We explored associations of these biomarkers with expression of CLDN18. Results: In GICC, frequent mutations were seen in TP53 (68%; 442), APC (33.5%; 218) and KRAS (33.3%; 217). PBCC, showed mutations in TP53 (62%; 197), KRAS (47%; 149) and CDKN2A (16%; 51). HCC showed mutations in TP53 (42%; 32), ARID1A (18%; 14) and KRAS (9%; 7). Amplifications were predominantly observed in MYC (13%; 120), ERBB2 (5%; 49) and CCND1 (5%; 44). Fusions were infrequent. All MSI-H cases (11/462; 2.4%) were observed in GICC. High TMB (≥10 muts/mb) was seen in 23% (111/481), stratified as 28% (90/318) in GICC, 13% (18/139) in PBCC and 10% (3/30) in HCC. Out of 321 samples analyzed for gene expression profiling, CLDN18 was significantly upregulated in 65 (20%) samples. The expression of CLDN18 did not show statistically significant correlation with Her2 (n=184), PD-L1 (n=231), TMB (n=228), or MSI (n=229); (p>0.05). In subset where both CLDN18 and MUC1 expression were analyzed (n=118), all the CLDN18 positive tumors showed overexpression of MUC1. This finding was statistically significant (p<0.05). Increased expression of MUC1 promotes cancer cell mobility promoting metastases. Expression of MUC1 can play an important role in the development of resistance to chemotherapy. MUC1 expression in cancer cells is associated with avoidance of immune defenses. Thus, this finding of CLDN18 and MUC1 association is especially relevant as the CLDN18 targeted therapies may be the potential avenue for the aggressive and chemo-resistant MUC1 expressing tumors. Conclusions: This study identifies potential association between MUC1 and CLDN18. GEP could enhance biomarker detection and support personalized treatment approaches. Future research should integrate these findings with clinical data to improve precision in GI cancer care.
Clinical and molecular characterization of <i>FAP</i> and <i>SPP1</i> in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data.
276 Background: FAP and SPP1 contribute to immune modulation in the CRC tumor microenvironment (TME). FAP is expressed by cancer associated fibroblasts, aiding in tissue remodeling and tumor invasion. SPP1 is an integrin-binding protein expressed by tumor associated macrophages that promotes tumor growth, adhesion, and metastasis. We present a clinical and molecular characterization of FAP and SPP1 in CRC. Methods: We analyzed 24,257 CRC samples tested at Caris Life Sciences (Phoenix, AZ) with WTS (Illumina NovaSeq), NextGen DNA sequencing (NextSeq), and PD-L1 expression (SP142, positive ≥ 2+, 5%). RNA deconvolution analysis estimated cell infiltration in the TME. Data from the phase 3 CALGB/SWOG 80405 trial (NCT00265850) on 433 metastatic CRC patients treated with bevacizumab (Bev, n = 226) or cetuximab (Cet, n = 207) in combination with first-line chemotherapy were also evaluated. RNA isolated from FFPE tumor samples were sequenced with HiSeq 2500 (Illumina). Overall survival (OS) and progression-free survival (PFS) were compared using Cox regression in categorical gene expression tertiles (high (T3), medium (T2), and low (T1)) for FAP and SPP1 . Results: FAP -T3 and SPP1 -T3 had increased PD-L1 positivity (q<0.05), while SPP1 -T3 also demonstrated increased MSI-H (8.4% vs 5.3%) and TMB-H(>10 mt/mb, 15.0% vs 10.1%) status relative SPP1 -T1 (all q<0.001). T3 of both genes of correlated with increased M1/M2 macrophages, NK cells and T cell inflamed score (q<0.001); dendritic cells and neutrophils were increased in SPP1 -T3 and FAP -T1 tumors (q<0.05). FAP -T3 and SPP1 -T3 had increased pathway activation of epithelial-mesenchymal transition (EMT), inflammatory response, TNF-a signaling, angiogenesis and KRAS signaling (all q < .005). In Caris cohorts, FAP -T3 demonstrated worse OS in Cet/panitumumab treated CRC (T3: 23.6 vs T1: 21.0 months [mo], P = .005; HR 0.85, 95% CI [0.77-0.95]), but SPP1 did not correlate with OS. In 80405, FAP -T3 showed shorter PFS (T3: 9.5 vs T2: 11.5 vs T1: 12.6 mo, T3 vs T1 (reference) adjusted HR 1.27 [1.07-1.51]) and OS (25.2 vs 29.4 vs 35.5 mo, adjusted HR 1.31 [1.10-1.57]). Similarly, SPP1 -T3 demonstrated worse PFS (9.0 vs 12.7 vs 14.0 mo, adjusted HR 1.29 [1.12-1.48]) and OS (20.9 vs 34.0 vs 36.3 mo, HR 1.24 [1.07-1.44], P < 0.001). Treatment interaction tests noted FAP -T1 CRC benefited from Cet over Bev with respect to PFS ( P = 0.003) and OS ( P = 0.044), while SPP1-T1 tumors demonstrated a PFS benefit with Cet ( P = 0.009). Conclusions: Our results indicate that increased FAP and SPP1 expression is associated with immune cell infiltration, EMT, and inflammatory signaling. Additionally, their expression may be prognostic and predictive of targeted therapy. These data support the evaluation of FAP and SPP1 as predictive markers and therapeutic targets in CRC.
INSTINCT: Multi-sample integration of spatial chromatin accessibility sequencing data via stochastic domain translation
Nanoparticle‐Mediated Explosive Anti‐PD‐L1 Factory Built in Tumor for Advanced Immunotherapy
AbstractImmunotherapy, particularly immune checkpoint blockade (ICB) therapies, has revolutionized oncology. However, it encounters challenges such as inadequate drug accumulation and limited efficacy against “cold” tumors characterized by lack of T cell infiltration and immunosuppressive microenvironments. Here, a controlled antibody production and releasing nanoparticle (CAPRN) is introduced, designed to augment ICB efficacy by facilitating tumor‐targeted antibody production and inducing photodynamic cell death. CAPRN achieves tumor‐specific accumulation via pH‐responsive PEG detachment, enabling efficient intracellular gene delivery encoding anti‐PD‐L1 antibody. Laser‐induced photodynamic therapy (PDT) not only triggers cancer cell death but also facilitates targeted antibody release from dying tumor cells. CAPRN demonstrates significant anti‐tumor efficacy, attributed to multiple effects including enhanced antibody release, dendritic cell (DC) maturation, and T cell activation. Moreover, CAPRN exhibits substantial tumor suppression in both primary and bilateral tumor models, accompanied by activated T cell infiltration and enhanced immune responses. This study presents a novel strategy for priming robust immunotherapy, offering targeted antibody release through laser‐assisted photodynamic nanoparticles.
Individual patient data (IPD) pooled analysis on the optimal therapeutic management of patients with microsatellite instability-high (MSI) resectable gastroesophageal adenocarcinoma (GEA).
455 Background: Patients with resectable MSI/dMMR GEA showed improved survival and modest if any benefit from chemotherapy. Preoperative treatment with immune checkpoint inhibition (ICI) showed high rate of major-complete pathologic response in single arm trials possibly allowing the design of chemotherapy/surgery-free approaches. Methods: This was a multinational IPD analysis including patients with resectable GEA with MSI/dMMR status enrolled in INFINITY and NEONIPIGA phase II trials, with dual CTLA-4/PD-(L)1 ICI followed by surgery +/- adjuvant ICI; PROSECCO retrospective study, with perioperative FLOT chemotherapy and surgery, and the dataset of our previous IPD analysis on MAGIC, CLASSIC, ARTIST and ITACA-S randomized trials of patients treated with surgery alone or plus older perioperative/adjuvant chemo(radio)therapy regimen. Primary endpoint was the evaluation of rates of pathologic complete response (pCR) defined as TRG1a Becker and major-complete pathologic response (pCR/MPR) defined as TRG1a/b Becker according to preoperative treatment schedule in patients who underwent surgery. Univariable and multivariable analyses were conducted using a random effects logistic model adjusted with propensity score. Secondary endpoints were event-free survival (EFS) and overall survival (OS) according to the therapeutic strategy in the overall study population. Multivariable mixed-effects Cox models weighted with propensity score were performed. Results: The IPD included 197 patients. Of these, 49 received ICI +/- surgery, 27 FLOT chemotherapy plus surgery, 33 surgery alone and 88 older chemo(radio)therapy regimens plus surgery. In the 69 patients resected after neoadjuvant ICI or FLOT standard of care treatment, ICI demonstrated a higher rate of pathologic response compared to chemotherapy (pCR 61.9% vs 3.7%, OR 54.8 p=0.002; pCR/MPR 78.6% vs 10%, OR 39.3 p<0.001). In ITT population, no significant difference in OS and EFS was shown in patients treated with ICI, FLOT plus surgery, old chemo(radio)therapy plus surgery or surgery alone. Conclusions: In resectable MSI/dMMR GEA, upfront ICI showed comparable survival outcomes to surgery alone, with limitations of study design and sample size. The impact on survival of ICI versus surgery alone should be investigated prospectively to avoid overtreatment or identify specific risk categories with benefit. The high rate of major-complete pathologic response may allow to study or perform organ sparing surgery procedures or non-operative management to reduce surgical morbidity/mortality and improve quality of life. OS EFS HR 2.5-97.5% CI p HR 2.5-97.5% CI p Ref: Surgery only - - - - - - Chemo+surgery 1.16 0.27-4.98 0.84 1.10 0.39-3.07 0.85 FLOT+surgery 1.10 0.19-6.22 0.92 2.38 0.90-6.27 0.08 ICI +/- surgery 1.97 0.43-8.96 0.38 1.39 0.51-3.77 0.52
Oncomine panel testing in the clinical management of colorectal cancer: An Irish experience.
212 Background: Early onset colorectal cancer (EOCRC) is defined as colorectal cancer (CRC) in those under the age of 50. It has been hypothesized that the molecular signatures of EOCRC could differ from those of late onset CRC (LOCRC). Next Generation Sequencing (NGS) using the Oncomine Precision Assay is a useful tool to guide treatment decisions based on the presence or absence of oncogene drivers. While not all of these mutations currently influence the clinical management of CRC patients, ongoing research on the function of these genes and the development of new drugs could offer insights into patient prognosis, treatment choices and prediction of therapy resistance. Methods: Of >1500 CRC identified between 2010 and 2024, we investigated the clinical and genetic characteristics of 38 EOCRC and 41 LOCRC cases. All cases were microsatellite stable and staged I-III. NGS was performed with the Ion Torrent Genexus integrated platform using the Oncomine 45-gene Precision Assay panel. DNA hotspot mutations and copy number variations (CNVs) were assessed, followed by the classification of clinically relevant mutations using the genetic variant OncoKB database. Results: There were 38 EOCRC and 41 LOCRC cases. The age range was 27 to 49 and 50 to 91, with median ages of 44 and 72, in the EOCRC and LOCRC groups, respectively. Based on the stratification of NGS mutation levels as per the OncoKB classification, all patients in both groups (100%) had level 1 actionable mutations. NRAS wild type (WT) status was present in 100% of patients in both groups. However, differences were observed in KRAS status: 84% (32/38) of EOCRC were KRAS WT, while only 65% (27/41) of LOCRC were KRAS WT. While 3 % (n=1) of the EOCRC cohort had an ERBB2 amplification, none were detected in the LOCRC group. BRAF V600E mutations were present in 11% (4/38) of EOCRC and 12% (5/41) of LOCRC. Level 4 mutations were detected in 18% (n=7) of EOCRC, all of which were PIK3CA mutations, while these were seen in 24% (n=10) of the LOCRC group, including 9 PIK3CA mutations and 1 FGFR1 mutation. Regarding concurrent mutations, 2 patients in the EOCRC group had two mutations each: one with concurrent KRAS and PIK3CA mutations, and another with concurrent JAK2 and KRAS mutations. The LOCRC group had a higher incidence of concurrent mutations, with 8 patients affected: 6 had concurrent KRAS and PIK3CA mutations, and 2 had concurrent BRAF and PIK3CA mutations. Conclusions: Our study demonstrates that EOCRC have higher KRAS WT status and fewer concurrent mutations compared to LOCRC, who exhibit more frequent KRAS non-G12C oncogenic mutations. It also underscores the importance of routine NGS mutation panel analysis in CRC management. Additionally, identifying specific mutations in patients that relapse can guide targeted therapies, potentially improving outcomes and offering personalized treatment options.
Prompt initiation of durvalumab and tremelimumab treatment for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B.
568 Background: Chronic hepatitis B virus (HBV) infection is a common etiology of HCC, especially in East Asia. Clinical trials using immune checkpoint inhibitors (ICIs) usually exclude patients with chronic active hepatitis B (serum HBV viral load > 2000 IU/mL) or require the HBV viral load to be below a certain level using anti-HBV medications. This study examines the safety and efficacy of concurrently administering the STRIDE regimen (durvalumab with a single dose of tremelimumab) or durvalumab alone with anti-HBV medications in this patient population. Methods: We enrolled patients with advanced HCC, Child-Pugh A liver function reserve, and untreated chronic active hepatitis B. Initially, only patients naïve to ICIs were eligible, and patients received 1500mg of durvalumab intravenously every four weeks for up to two years except for disease progression or occurrence of unacceptable toxicities. After the positive results of the HIMALAYA study, we shifted to the STRIDE (single tremelimumab regular interval durvalumab) regimen, adding one dose of 300mg tremelimumab on the first day to regular durvalumab treatment, and allowed patients who had received prior programmed cell death-1 blockade therapy to be enrolled. Anti-HBV treatment with entecavir was initiated within seven days before starting ICI therapy. The primary endpoint was the rate of HBV reactivation (defined as a ≥2 log increase in serum HBV DNA from baseline) during the first six months. Results: Following the protocol design, 30 patients were enrolled. Two patients were female, and the mean age was 66.9 years. Ten patients received durvalumab alone, and 20 received the STRIDE regimen. Macrovascular invasion and extrahepatic spread were present in 16 (53.3%) and 20 (66.7%) patients, respectively; 18 (60%) patients had alpha-fetoprotein level ≥ 400 ng/mL. More than half (60.0%) of the patients had received prior systemic therapy for HCC, including 2 patients who had received PD-1 blockade therapy. Seven patients received the study treatment as the 3 rd or later line of systemic therapy. The mean±standard deviation baseline HBV viral load was 771.0±354.1 KIU/mL. No patients experienced HBV reactivation or HBV-associated hepatitis. Hepatitis flare was noted in 8 (26.7%) patients, but none of them were associated with HBV reactivation. The objective tumor response rate was 10% and 25% for the durvalumab treatment alone and the STRIDE regimen, respectively. No unexpected toxicities were identified in this study. The most common treatment-related adverse events were skin rash and liver function test abnormalities. Conclusions: For patients with chronic active hepatitis B, ICI therapy could be promptly initiated as long as anti-HBV medications were administered simultaneously. This study was partially supported by AstraZeneca. Clinical trial information: NCT04294498 .
KAI2-dependent signaling controls vegetative reproduction in Marchantia polymorpha through activation of LOG-mediated cytokinin synthesis
3D‐Printed Electrohydrodynamic Pump and Development of Anti‐Swelling Organohydrogel for Soft Robotics
Abstract This study introduces advancements in electrohydrodynamic (EHD) pumps and the development of a 3D‐printable anti‐swelling organohydrogel for soft robotics. Using digital light processing (DLP)technology, precise components with less than 1% size variation are fabricated, enabling a unique manifold pump array. This design achieves an output pressure of 90.2 kPa—18 times higher than traditional configurations—and a flow rate of 800 mL min −1 , surpassing previous EHD pumps. To address swelling issues in dielectric liquids, a novel organohydrogel is developed with Young's modulus of 0.33 MPa, 300% stretchability, and a swelling ratio under 10%. Its low swelling is attributed to the shield effect and edge length confinement effect. This durable material ensures consistent pump performance under mechanical stresses like bending and twisting, crucial for dynamic soft robotic environments. These innovations significantly improve EHD pump efficiency and reliability, expanding their potential applications in soft robotics, bioengineering, and vertical farming.
CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
TPS507 Background: GC/GEJC is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide (Sung H, et al. CA Cancer J Clin 2021). Prognosis is poor in GC/GEJC; median overall survival (OS) is less than 10 months in the 2L setting and less than 6 months in the 3L+ setting (Wilke H, et al. Lancet Oncol 2014; Shitara K, et al. Lancet Oncol 2018). New treatment options are needed. CLDN18.2 has emerged as a new therapeutic target in GC/GEJC. AZD0901, a potential first-in-class CLDN18.2-targeted antibody conjugated to monomethyl auristatin E via a protease cleavable linker, has demonstrated clinical activity in a Phase 1 study in advanced GC/GEJC (Xu R-H, et al, J Clin Oncol 2023). CLARITY-Gastric 01 (NCT06346392) is a randomized, open-label, sponsor-blinded, global Phase 3 study that will assess the efficacy and safety of AZD0901 versus investigator’s (INV) choice of therapy after ≥1 prior therapy for advanced GC/GEJC expressing CLDN18.2. Methods: Participants (pts) will be randomized 1:1:1 to AZD0901 dose level 1 intravenous (IV) every three weeks (Q3W; Arm 1), AZD0901 dose level 2 IV Q3W (Arm 2), or INV choice of therapy (2L: ramucirumab [ram] + paclitaxel [PTX], PTX, or docetaxel [for pts with contraindication to ram only]; 3L+: irinotecan, TAS-102 [excluding China], or apatinib [China only]; Arm 3). One AZD0901 arm (Arm 1 or Arm 2) will stop enrollment after a pre-planned dose selection decision. Randomization will continue in a 1:1 ratio to the two remaining arms (selected AZD0901 dose arm and Arm 3). Eligible pts must have histologically confirmed, unresectable, locally advanced or metastatic GC/GEJC (non-HER2+, CLDN18.2 expression). Pts must have disease progression on/after ≥1 prior regimen (including platinum-fluoropyrimidine) and have an ECOG performance status of 0 or 1. Pts previously treated with CLDN18.2-targeting therapy (other than naked monoclonal antibody) are excluded. Recruitment has begun and pts are planned to be enrolled across 16 countries in Asia, Europe, and North America. Dual primary endpoints are progression-free survival (PFS; intent-to-treat [ITT] pts) and OS (3L+ pts). The secondary endpoints include OS (ITT pts), PFS (3L+ pts), objective response rate and duration of response (ITT and 3L+ pts), and safety/tolerability. Efficacy data will be summarized and analyzed in the ITT population. All efficacy endpoints will assess the selected AZD0901 dose arm versus Arm 3. Safety and tolerability will be assessed in all pts who receive ≥1 dose of study treatment. Previously presented at European Society for Medical Oncology - Gastrointestinal Cancers Congress 2024, Final Publication Number: 495TiP, Kohei Shitara et al. Reused with permission. Clinical trial information: NCT06346392 .
Results of a multicenter retrospective cohort study evaluating the safety and efficacy of FTD/TPI plus ramucirumab in advanced gastric cancer (HGCSG2302).
351 Background: In advanced gastric cancer, trifluridine/tipiracil (FTD/TPI) is one of the standard treatments for later-line chemotherapy. Ramucirumab (RAM), an anti-VEGFR-2 monoclonal antibody, has shown promising efficacy in combination with FTD/TPI in phase II studies conducted in Japan, suggesting that this combination could improve treatment outcomes. However, there remains a paucity of real-world clinical data comparing the efficacy and safety of FTD/TPI monotherapy and FTD/TPI plus RAM combination therapy in general clinical practice. Methods: This retrospective analysis to evaluate safety and efficacy included patients with gastric cancer who were received FTD/TPI plus RAM combination therapy or FTD/TPI monotherapy between August 2019 and March 2023 at 21 institutions. Results: 164 patients were analyzed, 38 patients in the RAM combination group and 126 in the FTD/TPI monotherapy group. The distribution of treatment lines (third/fourth/fifth) was 10/13/15 in the RAM group and 26/54/46 in the monotherapy group, respectively. RAM had been previously administered to 34 patients (89.5%) in the RAM group. Objective response rate and disease control rate were 11.1% / 55.6% (OR 2.0, 95% C.I. 0.84-4.77, p=0.126) in the RAM group and 5.5% /38.5% (OR 2.0, 95% C.I. 0.84-4.77, p=0.126) in the monotherapy group, respectively. Median progression-free survival (PFS) was 3.5 months in the RAM group and 2.1 months in the monotherapy group (HR 0.69, 95% C.I. 0.49-1.02, p=0.06), respectively. Median overall survival (OS) was 8.4 months in the RAM group and 5.8 months in the monotherapy group (HR 0.82, 95% C.I. 0.54-1.25, p=0.350), respectively. Grade 3 neutropenia was reported in 48.6%/52.4% (p=0.707), and there were no significant differences in other adverse event profiles between the two groups. Additionally, in the RAM group, a comparison between patients receiving standard dosing (2 weeks on/2 weeks off; n=7) and those on biweekly dosing (1 week on/1 week off; n=24) showed no notable differences in efficacy or safety. Conclusions: FTD/TPI plus RAM combination therapy showed a trend toward prolonged PFS compared to FTD/TPI monotherapy, but no significant difference in OS.
Disease-free survival as a surrogate endpoint for overall survival in adults with early-stage pancreatic cancer: A trial-level surrogacy analysis.
708 Background: In early-stage cancer, overall survival (OS) is the gold-standard endpoint for assessing therapeutic efficacy. However, long follow-up periods make OS challenging and costly to measure in clinical trials. Disease-free survival (DFS), which captures the time to recurrence or death, has been proposed as a surrogate endpoint for OS in early-stage pancreatic cancer (PC). This surrogacy relationship could allow for a more rapid assessment of treatment benefits, but its validity requires robust analysis across clinical trials. Understanding the trial-level correlation between DFS and OS is crucial to optimizing trial design and grant accelerated drug approval. Methods: We conducted a systematic search of Embase, PubMed, and Cochrane databases through August 2024, identifying randomized controlled trials (RCTs) that evaluated adjuvant or neoadjuvant systemic therapies in adult patients with PC. Included studies reported both OS and DFS outcomes. Hazard ratios for DFS (HR_DFS) were analyzed as surrogate endpoints for OS (HR_OS). Statistical analyses utilized linear regression models, weighted by trial sample sizes, to determine the strength of the correlation. Surrogacy strength was categorized by the coefficient of determination (R²), with R² ≥ 0.7 indicating a strong correlation, 0.69–0.5 a moderate correlation, and values < 0.5 indicating weak correlation. Results: Out of 3,048 studies screened, 30 RCTs met the inclusion criteria, comprising 5,275 patients in adjuvant therapy trials and 557 patients in neoadjuvant therapy trials. The median follow-up duration ranged from 16 to 53.5 months, with 12 phase II trials included. Overall, DFS showed strong surrogacy for OS in adjuvant trials (R² = 0.70; 95% CI, 0.50–0.91). Subgroup analysis indicated strong correlation in phase III trials (R² = 0.71; 95% CI, 0.46–0.96) and moderate correlation in phase II trials (R² = 0.67; 95% CI, 0.21–1.00). The strongest surrogacy was observed in studies incorporating adjuvant radiation therapy (R² = 0.81; 95% CI, 0.52–1.00). In the analysis of neoadjuvant trials, HR-DFS also presented strong correlation with OS (R² = 0.90; 95% CI, 0.56–1.00). Conclusions: There is a strong trial-level correlation between DFS and OS in both adjuvant and neoadjuvant therapy trials for early-stage pancreatic cancer, particularly in phase III studies and trials incorporating adjuvant radiation therapy. However, the strength of this surrogacy varies depending on the treatment setting and trial design.
Rapid learning with phase-change memory-based in-memory computing through learning-to-learn
Abstract There is a growing demand for low-power, autonomously learning artificial intelligence (AI) systems that can be applied at the edge and rapidly adapt to the specific situation at deployment site. However, current AI models struggle in such scenarios, often requiring extensive fine-tuning, computational resources, and data. In contrast, humans can effortlessly adjust to new tasks by transferring knowledge from related ones. The concept of learning-to-learn (L2L) mimics this process and enables AI models to rapidly adapt with only little computational effort and data. In-memory computing neuromorphic hardware (NMHW) is inspired by the brain’s operating principles and mimics its physical co-location of memory and compute. In this work, we pair L2L with in-memory computing NMHW based on phase-change memory devices to build efficient AI models that can rapidly adapt to new tasks. We demonstrate the versatility of our approach in two scenarios: a convolutional neural network performing image classification and a biologically-inspired spiking neural network generating motor commands for a real robotic arm. Both models rapidly learn with few parameter updates. Deployed on the NMHW, they perform on-par with their software equivalents. Moreover, meta-training of these models can be performed in software with high-precision, alleviating the need for accurate hardware models.
Highly Efficient Monolithic Perovskite/TOPCon Silicon Tandem Solar Cells Enabled by “Halide Locking”
Abstract Perovskite/silicon tandem solar cells (TSCs) are promising candidates for commercialization due to their outstanding power conversion efficiencies (PCEs). However, controlling the crystallization process and alleviating the phases/composition inhomogeneity represent a considerable challenge for perovskite layers grown on rough silicon substrates, ultimately limiting the efficiency and stability of TSC. Here, this study reports a “halide locking” strategy that simultaneously modulates the nucleation and crystal growth process of wide bandgap perovskites by introducing a multifunctional ammonium salt, thioacetylacetamide hydrochloride (TAACl), to bind with all types of cations and anions in the mixed halide perovskite precursor. The approach not only enables excellent compositional uniformity in the wet‐film stage but also induces preferred orientation along the (001) plane following nucleation, leading to enhanced homogeneity of the perovskite film in both vertical and horizontal directions over long‐length scales. The resulting wide‐bandgap perovskite solar cells yield exceptional open‐circuit voltage‐fill factor products ( V OC × FF) of 1.074 and 1.040 in small‐ (0.0414 cm 2 ) and large‐area (1.0208 cm 2 ) devices, respectively. Corresponding large‐area tandem solar cells based on the Tunnel Oxide Passivated Contact (TOPCon) silicon subcells achieve a record PCE of 31.32% with a remarkable V OC of 1.931 V and FF of 81.54%.
Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.
676 Background: Data is lacking to guide the care of vulnerable older adults (OA) with newly diagnosed metastatic pancreatic adenocarcinoma (mPDAC). EA2186 trial demonstrated poor outcomes among vulnerable OA with mPDAC treated with dose-reduced chemotherapy. To understand the factors driving treatment outcomes in this patient population, we analyzed the correlation between baseline geriatric and quality of life (QOL) assessments and treatment outcomes. Methods: Vulnerable OA ≥70 yo with mPDAC, ECOG PS 0-2 were enrolled. Vulnerability was defined by screening geriatric assessment (GA) demonstrating mild abnormalities in function, comorbidities, cognition, or age≥80y. Pts were randomized to Arm A: Gemcitabine (1000mg/m2) + Nab-Paclitaxel (125mg/m2) q14 days or Arm B: 5-Fluorouracil (2400mg/m2 46hr) + Leucovorin (400mg/m2) + Liposomal Irinotecan (50mg/m2) q14 days. GA and QOL evaluations were completed at baseline and 3 time points. Secondary endpoints of the study included evaluating the correlation between baseline GA, QOL and treatment outcomes. Regression models were used to evaluate the associations between baseline GA and QOL factors, survival and grade 3 or higher toxicity, with 80% power to detect doubling in grade 3 toxicity for GA/QOL measures. Results: 176 pts (88 per arm) enrolled with median age 77 (range 70-90), 24% ECOG-0, 64% ECOG-1 and 12% ECOG-2. Pts were deemed vulnerable by cognition (46%), age (36%) or comorbidities (31.4%), with 35% meeting vulnerability criteria in ≥2 domains. No significant difference was seen in median OS (4.7 vs. 4.4 months; p=0.72) or ≥grade 3 toxicity rate (45.6% vs. 58.7%; p=0.10) between arms A and B, respectively. Strong correlation was found between OS and baseline instrumental activities of daily living score (HR 0.84; p=0.02), nutritional scores (HR 0.82; p<0.0001), depression scores (HR 1.07; p=0.02), and scores of all QOL measures (HR 0.98; p<0.0001). No correlation was found between OS and comorbidity, cognition, and Activities of Daily Living scores. After adjustment for age and PS, only baseline WBC level (OR=0.35; p=0.0054), and depression scores (OR=1.20 per score unit; p=0.021) and to a lesser extent FACT-G score (OR=0.98 per score unit; p=0.061) were found to correlate with rates of ≥grade 3 toxicity. Conclusions: Baseline GA and QOL factors among vulnerable older adults with mPDAC correlate strongly with survival and treatment tolerance. Supportive care to address these factors may favorably affect outcomes in this patient population. Clinical trial information: NCT04233866 .
HCC in the Rio Grande Valley: Outcomes in a predominant Latino community.
550 Background: Hepatocellular carcinoma (HCC) has slowly increased in the U.S. in recent years, with a higher incidence among racial and ethnic minorities, particularly Latinos. This retrospective study examines the different etiologies, presentation of diagnosis, management, and outcomes of patients presented in a multidisciplinary-liver tumor board in the Rio Grande Valley, home of 1.3 million Latinos. Methods: A retrospective chart review was conducted on patients with HCC diagnosis who were presented at the Liver Tumor Board of DHR Health Transplant Institute between 2017 and 2023. The data collected was extracted from the EHR, including medical history, laboratory results, and radiological studies required for staging, transplant eligibility assessments, clinical characteristics, and treatments. Results: A total of 250 cases were reviewed, and 70 patients with complete clinical data and a diagnosis of HCC were included in the study. Of those, 98.5% were identified as White/ Hispanic. The median age at diagnosis was 64.4 ± 9.2 years, with 72.9% male and 11.4% uninsured. The average BMI was 31.5 kg/m 2 , metabolic-associated liver disease (MALD) was present in 28.6% of patients, 25.7% were alcohol-related, and 38.6% presented multiple etiologies. A descriptive analysis of this population is found in the table. Ablative therapy was used in 68 (97.1%) of the patients. The number of patients sent for liver transplant evaluation was 31 (44%), and only 3 (4.2%) patients received a liver transplant. Barriers to transplant included lack of transportation, inadequate social support, underinsurance, and fear of the transplant itself. Conclusions: Our data by staging aligns with the national distribution of incidence cases from 2012-2022 per SEER program. The rate of transplantation at our institution is below the national average, highlighting the need to bridge this disparity and address race-specific barriers to transplant within the Latino community. Sociodemographic data. Parameter Stage IAN=15 (21.4%) Stage IBN=20 (28.6%) Stage IIN=10 (14.3%) Stage IIIAN=8 (11.4%) Stage IIIBN=9 (12.9%) Stage IVAN=5 (7.1%) Stage IVBN=3 (4.3%) All StagesN=70 (100%) Child Pugh A 7 (46.7%) 8 (40.0%) 5 (50.0%) 4 (50.0%) 2 (22.2%) 2 (40.0%) 1 (33.3%) 29 (41.4%) Child Pugh B 6 (40.0%) 6 (30.0%) 5 (50.0%) 2 (25.0%) 5 (55.6%) 2 (40.0%) 2 (66.7%) 28 (40.0%) Child Pugh C 2 (13.3%) 6 (30.0%) 0 (0.0%) 2 (25.0%) 2 (22.2%) 1 (20.0%) 0 (0.0%) 13 (18.6%) MELD-Na mean, (min-max) 12.8(7.0-21.0) 13.6(6.0-23.0) 12.8(6.0-20.0) 12.3(5.0-17.0) 13.6(8.0-26.0) 13.0(10.0-19.0) 11.3(7.0-14.0) 13.6(6.0-26.0) Therapy*:Ablative (TACE, Y90, Radiation, other) 15 21 10 6 8 6 2 Surgery (including transplant)** 1 1 2 2 2 0 0 Systemic 2 6 5 4 6 3 1 Overall Survival (months) 29.5 26.8 34.7 17.5 24.1 17.3 14.9 25.3 *Several patients received one or more types of therapy. **All transplant patients received ablation therapy.
Avutometinib plus cetuximab after chemotherapy in patients with <i>KRAS</i> -mutated metastatic colorectal cancer: Results of phase 1 dose escalation.
199 Background: Anti-EGFR antibodies like cetuximab are ineffective in KRAS mutated (mt) colorectal cancer (CRC) due to constitutive activation of downstream pathways. Avutometinib is a first in class, oral, novel, dual RAF/MEK inhibitor. In patient-derived xenograft models of KRAS mt CRC, the combination of an anti-EGFR antibody with avutometinib conferred stronger tumor growth inhibition than either agent alone. We present results from the dose escalation phase (1b) of an ongoing phase 1b/2 trial evaluating the combination avutometinib plus cetuximab in KRAS mt metastatic (m) CRC. Methods: This is a single-center, open-label, phase 1b/2 study evaluating the safety and combined tolerability of avutometinib and cetuximab. Patients received avutometinib 2.4mg (at DL0) or 3.2mg (at DL1) orally twice a week for 3 weeks out of a 4-week cycle + cetuximab 500mg/m 2 intravenously q2week. Patients with disease progression on, or intolerance to 5-FU, oxaliplatin, and irinotecan, and measurable disease per RECIST v1.1 were enrolled. The primary endpoint for phase 1b was to establish the maximum tolerated dose (MTD) and hence determine the recommended phase 2 dose (RP2D). Dose limiting toxicity (DLT) period was 28 days. A 3+3 dose escalation design was used with dose level (DLs) 0 (2.4mg avutometinib) as the starting level and one dose escalation to DL+1 (3.2mg avutometinib). Results: We report safety results of phase 1b. 10 patients, 7 at DL0 and 3 at DL+1, were enrolled. Median age was 52.5 yrs (range 41 – 75). Any grade (G) treatment related adverse events (TRAEs) were seen in all 10 patients. Most common TRAEs were acneiform rash (100%), chills (30%), diarrhea (30%), and fatigue (30%). G3 TRAEs at DL0 were seen in 4/7 (57.1%) patients and at DL+1 in 2/3 (66.7%) patients. No G4 TRAEs were seen. G3 TRAEs seen at DL0 are noted in the table. One patient from the initial three enrolled was not evaluable due to underdosing. Another patient was later found to not meet eligibility criteria, but they did clear the DLT period. Hence, 6/7 patients at DL0 were evaluated for AE assessment, of which 1 had a DLT. 3 additional patients were enrolled in DL+1. 2/3 patients in DL+1 had grade 3 toxicities (both DLTs) of rash. Hence DL0 was established as the MTD/RP2D. Conclusions: This is the first trial evaluating the combination avutometinib plus cetuximab in KRAS mt mCRC. RP2D for avutometinib was established at 2.4mg orally twice a week for 3 weeks out of a 4-week cycle when used in combination with q2week 500mg/m 2 cetuximab for KRAS mt mCRC. Enrollment continues currently for the dose expansion phase for efficacy assessment. Clinical trial information: NCT05200442 . G3 TRAEs at DL0 attributed to both drugs unless specified. G3 TRAE # of patients Acneiform rash 3/7 (42.9%) Hand-Foot syndrome 1/7 (14.3%) Extremity edema 1/7 (14.3%) Cellulitis 1/7 (14.3%) Sepsis 1/7 (14.3%) Anemia 1/7 (14.3%) Creatine phosphokinase elevation 1/7 (14.3% – avutometinib only)